- The researchers found that microdosing psychedelics may positively influence well-being and reduce ADHD symptoms in adults over a period of weeks.
- A significant interaction existed between time and medication use, indicating that those using conventional ADHD medications alongside microdosing exhibited different symptom changes compared to those using only microdoses.
- Despite some positive effects, the study highlighted limitations, including a high dropout rate and the absence of a placebo control, suggesting that further rigorous studies are necessary.
Introduction to ADHD in Adults
Attention deficit hyperactivity disorder (ADHD) is not just a childhood condition; it also persists into adulthood for a notable portion of the population. Researchers estimate that approximately 2.6% of adults continue to experience symptoms related to ADHD. This chronic condition can lead to severe repercussions in various areas of life, including financial difficulties, increased risk of criminal behavior, and higher rates of suicidality, ultimately diminishing an individual’s overall quality of life.
Current Treatments and Their Limitations
The standard treatments for adult ADHD primarily involve pharmacological methods designed to enhance the functioning of certain neurotransmitters, specifically dopaminergic and noradrenergic systems. Common medications include stimulants like methylphenidate and amphetamines, as well as non-stimulants like atomoxetine. However, it is not uncommon for many adults to not respond adequately to these medications, negatively impacting their quality of life and necessitating the exploration of alternative treatment options.
Microdosing as an Alternative Therapy
In this context, microdosing, which involves administering classical psychedelics in small, repeated amounts, has been proposed as a possible alternative treatment for addressing ADHD symptoms. Despite anecdotal evidence suggesting benefits from this approach, comprehensive research to evaluate behavioral changes resulting from microdosing in adults with ADHD is still required.
Study Design and Participants
This survey-based study aimed to assess the effects of microdosing psychedelics in adults self-medicating for ADHD symptoms. It specifically looked at the participants’ experiences with ADHD treatment and whether concurrent use of conventional ADHD medications impacted the results. The authors recruited participants through online platforms familiar with microdosing practices, obtaining informed consent and gathering necessary demographic and medical information before the study commenced.
Data Collection and Assessment
The study involved the collection of data through surveys administered before microdosing began and again two and four weeks later. Participants also maintained diaries documenting their dosage and substances used throughout the study, allowing for more detailed insight into their microdosing practices. To measure the severity of ADHD symptoms, the study utilized various validated questionnaires, including the CAARS-S:SV and the WHO-5 Well-Being Index, along with an auditory time reproduction task to gauge time perception.
Participants and Findings
Out of 356 individuals who initially consented to participate, 247 completed the baseline survey and continued to participate through the follow-up assessments. Notably, a significant proportion of the participants had one or more comorbid psychiatric or physical disorders, which could influence treatment outcomes. After two weeks of microdosing, participants demonstrated a marked decrease in ADHD symptoms and an uptick in well-being metrics, with these improvements persisting through the four-week mark.
Details on Time Perception
However, contrary to expectations regarding time perception improvements, the study found that performance remained unchanged across the board. Interestingly, participants who utilized conventional ADHD medications alongside microdosing tended to overestimate intervals in a time estimation task, suggesting a complex interplay between various treatment modalities.
Limitations and Future Research Directions
The study acknowledged certain limitations, notably the lack of a placebo control group and a significant dropout rate, which may introduce bias into the findings. Furthermore, the reliance on self-reported data in diaries resulted in missing information. Given these limitations, the authors emphasized the necessity for future placebo-controlled trials to validate the therapeutic potential of microdosing for ADHD treatment, recommending that such studies also explore the effects on other conditions like substance use disorders or personality disorders.
Conclusion
This research represents an early step towards validating microdosing as a feasible treatment option for ADHD in adults, potentially affirming its therapeutic value, although further meticulous studies are essential to establish conclusive evidence.
Read the full paper summary on Blossom.
